SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
X	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* BULLOCK LAWRENCE E (Last) (First) (Middle) BIOMIMETIC THERAPEUTICS, INC. 389 NICHOL MILL LANE (Street) FRANKLIN TN 37067 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol BIOMIMETIC THERAPEUTICS, INC. [ BMTI ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Chief Financial Officer
	3. Date of Earliest Transaction (Month/Day/Year) 03/01/2013
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2013		D		89,151(1)	D	(2)	0	D
Common Stock	03/01/2013		D		21,000(3)	D	(2)	0	I	By Children(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$2.87	03/01/2013		D			112,500	(5)	01/12/2014	Common Stock	112,500	(5)	0	D
Stock Options (right to buy)	$12.59	03/01/2013		D			27,000	(6)	01/16/2017	Common Stock	27,000	(6)	0	D
Stock Options (right to buy)	$14.41	03/01/2013		D			25,000	(7)	02/07/2018	Common Stock	25,000	(7)	0	D
Stock Options (right to buy)	$8.54	03/01/2013		D			30,000	(8)	02/26/2019	Common Stock	30,000	(8)	0	D
Stock Options (right to buy)	$11.97	03/01/2013		D			37,500	(9)	02/03/2020	Common Stock	37,500	(9)	0	D
Stock Options (right to buy)	$13.45	03/01/2013		D			40,000	(10)	01/19/2021	Common Stock	40,000	(10)	0	D
Stock Options (right to buy)	$2.08	03/01/2013		D			80,000	(11)	02/28/2022	Common Stock	80,000	(11)	0	D

Explanation of Responses:

1. Includes shares acquired by the Reporting Person since the previous Form 4 filing (on 3/21/2012), consisting of 9,047 shares purchased through the Issuer's Employee Stock Purchase Plan and 1,381 shares awarded to his 401(k) Profit Sharing Plan account via the 2012 Company match.

2. Disposed of pursuant to the Agreement and Plan of Merger ("Merger Agreement") dated as of November 19, 2012, by and among the Company, Wright Medical Group, Inc. ("Wright"), Achilles Merger Subsidiary, Inc. and Achilles Acquisition Subsidiary, LLC in exchange for the following merger consideration per share of the Company's common stock: (a) $1.50 in cash, without interest; (b) 0.2482 of a share of Wright's common stock; and (c) one contingent value right ("CVR") issued by Wright.

3. Excludes 7,000 shares reported by the Reporting Person on the previous Form 4 filing (on 3/21/2012), as those shares are held in a trust fund which became wholly owned by the Reporting Person's son upon reaching the age of 21. Mr. Bullock no longer has pecuniary interest in them.

4. Mr. Bullock disclaims beneficial ownership of these shares except to the extent of his pecuniary interest in them.

5. Pursuant to the Merger Agreement, the stock options granted by the issuer converted into options to purchase 58,704 shares of Wright common stock at an exercise price of $5.50 per share.

6. Pursuant to the Merger Agreement, the stock options granted by the issuer converted into options to purchase 14,089 shares of Wright common stock at an exercise price of $24.13 per share.

7. Pursuant to the Merger Agreement, the stock options granted by the issuer converted into options to purchase 13,045 shares of Wright common stock at an exercise price of $27.62 per share.

8. Pursuant to the Merger Agreement, the stock options granted by the issuer converted into options to purchase 15,654 shares of Wright common stock at an exercise price of $16.37 per share.

9. Pursuant to the Merger Agreement, the stock options granted by the issuer converted into options to purchase 19,568 shares of Wright common stock at an exercise price of $22.94 per share.

10. Pursuant to the Merger Agreement, the stock options granted by the issuer converted into options to purchase 20,872 shares of Wright common stock at an exercise price of $25.78 per share.

11. Pursuant to the Merger Agreement, the stock options granted by the issuer converted into options to purchase 41,745 shares of Wright common stock at an exercise price of $3.99 per share.

Remarks:

	/s/ Ginger Owens Smith, Attorney-in-Fact for Lawrence E. Bullock	03/05/2013
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.